Story perspectives

Boston Scientific to Acquire Penumbra for $14.5 Billion

1/15/2026

Summary

Story summary

Boston Scientific announced it will acquire Penumbra for $14.5 billion, valuing Penumbra at $374 per share and a 19% premium.
The deal strengthens Boston Scientific's cardiovascular portfolio, in mechanical thrombectomy and neurovascular markets, and the company expects initial earnings dilution.
Penumbra shareholders may elect cash or stock, and Penumbra's CEO will join Boston Scientific's board.
The closing is expected in 2026, subject to regulatory approvals and shareholder consent.

1 of 1

Story summary

Boston Scientific announced it will acquire Penumbra for $14.5 billion, valuing Penumbra at $374 per share and a 19% premium.
The deal strengthens Boston Scientific's cardiovascular portfolio, in mechanical thrombectomy and neurovascular markets, and the company expects initial earnings dilution.
Penumbra shareholders may elect cash or stock, and Penumbra's CEO will join Boston Scientific's board.
The closing is expected in 2026, subject to regulatory approvals and shareholder consent.